Suppr超能文献

重组组织型纤溶酶原激活剂成功治疗一名需要腹膜透析患者的静脉闭塞性疾病。

Successful treatment of veno-occlusive disease with recombinant tissue plasminogen activator in a patient requiring peritoneal dialysis.

作者信息

Simpson D R, Browett P J, Doak P B, Palmer S J

机构信息

Department of Haematology, Auckland Hospital, New Zealand.

出版信息

Bone Marrow Transplant. 1994 Oct;14(4):635-6.

PMID:7858540
Abstract

There have been encouraging reports of the use of recombinant tissue plasminogen activator (tPA) in established veno-occlusive disease (VOD). Haemodialysis has been considered a contraindication to this therapy in view of the potential haemostatic complications. We report a case of a woman who developed moderately severe VOD complicated by anuria following an allogeneic bone marrow transplant for relapsed acute myeloid leukaemia. Following initiation of peritoneal dialysis she received tPA at a dose of 10 mg/day for 5 days. There was rapid improvement in her urine output and liver function with no bleeding complications. This case suggests that the requirement of dialysis may not preclude the use of tPA in established VOD and therefore warrants further study.

摘要

已有关于重组组织型纤溶酶原激活剂(tPA)用于已确诊的静脉闭塞性疾病(VOD)的令人鼓舞的报道。鉴于潜在的止血并发症,血液透析一直被视为该疗法的禁忌证。我们报告一例女性患者,她在接受异基因骨髓移植治疗复发的急性髓系白血病后发生了中度严重的VOD并伴有无尿。在开始腹膜透析后,她接受了剂量为每日10毫克的tPA治疗,持续5天。她的尿量和肝功能迅速改善,且无出血并发症。该病例表明,透析需求可能并不排除在已确诊的VOD中使用tPA,因此值得进一步研究。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验